Independent report by the Commission on Human Medicines on the
safety implications of a proposal to restrict the availability of
puberty blockers for under 18s.
Commission on Human Medicines
report on proposed permanent order to restrict the sale and
supply of GnRH agonists in children and young people under 18
years of age for the purpose of puberty suppression in gender
incongruence and/or gender dysphoria
Details
The report is technical and may not be easily interpreted by
non-experts. See a factsheet designed to help
readers interpret the report.
On 20 August 2024, a targeted consultation (Proposed changes to the
availability of puberty blockers for under 18s) was issued on
proposals to introduce a permanent order restricting the sale and
supply of gonadotropin-releasing hormones (GnRH) agonists in
children and young people under 18 years for the purpose of
puberty suppression in respect of gender dysphoria, gender
incongruence, or a combination of both, via restrictions to UK
private and European Economic Area (EEA) prescriptions.
The Secretary of State for Health and Social Care and the
Minister of Health for Northern Ireland jointly consulted the
Commission on Human Medicines (CHM) on these proposals,
as is required when deciding whether to legislate under the 1968
Medicines Act.
This independent report provides the view of CHM on the proposal
and makes 8 recommendations.
The government published its response to the consultation on 11
December 2024.
Note that GnRH agonists (or
GnRH
analogues) are also known as puberty blockers.
